A1C Levels and Insulin Requirements Are Shown to Decrease When Patients with Diabetes Switch to Valeritas’ V-Go® Device Coupled with Diabetes Education
Results of real world study and analyses presented in a poster at AADA 2015
BRIDGEWATER, N.J., August 6, 2015 – Valeritas Inc. announced today the most recent set of real-world study data and retrospective analyses reported by Diabetes America on Valeritas’ lead product, the V-Go Disposable Insulin Delivery Device. The data, collected from electronic records, and the analyses were presented in a poster presentation at the American Association of Diabetes Educators meeting in New Orleans, Louisiana, August 5-8, 2015. The data disclosed at AADA 2015 supports scientific findings and associated analyses presented earlier this year in posters at ADA 2015, AMCP 2015 and AACE 2015.
V-Go is a simple, wearable, basal-bolus insulin delivery solution for patients with diabetes that enables patients to administer a continuous, preset basal rate of insulin over 24 hours and provides on demand bolus dosing at mealtimes with U-100 fast acting insulin.
The poster titled, CLINICAL EFFICACY WITH V-Go® DISPOSABLE INSULIN DELIVERY DEVICE IN PATIENTS WITH DIABETES - SUPPORTED BY DIABETES EDUCATION , evaluated the changes that occurred when switching patients with diabetes to V-Go and the benefits of having diabetes education support. Data was collected from 21 patients with an average age of 56, an average baseline A1C of 9.7% and a mean duration of diabetes of 15 years. The results showed that switching patients to V-Go along with diabetes education provided a simple way to deliver basal-bolus insulin therapy and resulted in significant A1C reductions with less insulin.
“Finding safe and effective ways to reduce A1C levels with less insulin is paramount to successful diabetes management. This is why today’s news is particularly relevant. We see from this real world study conducted by Diabetes America that educating about diabetes makes a positive clinical impact on patients who have switched to V-Go,” said Valeritas CEO Ms. Kristine Peterson.
To receive a copy of the poster, please contact, [email protected].
About the V-Go® Disposable Insulin Delivery Device
V-Go is a small, discreet, wearable and easy-to-use disposable insulin delivery solution for the delivery of basal-bolus insulin therapy in adults with Type 2 diabetes. V-Go enables patients to closely mimic the body's normal physiologic pattern of insulin delivery by releasing a single type of insulin at a continuous preset basal rate over a 24–hour period and also providing for on-demand bolus dosing at mealtimes. V-Go is mechanical and operates for 24 hours without electronics, batteries, infusion sets or programming. It is worn on the skin under clothing and measures just 2.4 inches wide by 1.3 inches long by 0.5 inches thick, weighing approximately one ounce when filled with insulin.
Important Risk Information: If regular adjustments or modifications to the basal rate of insulin are required in a 24-hour period, or if the amount of insulin used at meals requires adjustments of less than 2-Unit increments, use of the V-Go Disposable Insulin Delivery Device may result in hypoglycemia. The following conditions may occur during insulin therapy with V-Go: hypoglycemia (low blood glucose) or hyperglycemia (high blood glucose). Other adverse reactions associated with V-Go use include skin irritation from the adhesive pad or infections at the infusion site. V-Go should be removed before any magnetic resonance imaging (MRI) testing.
About Valeritas, Inc.
Valeritas is a commercial-stage medical technology company focused on developing innovative technologies to improve the health and quality of life of people with Type 2 diabetes. Valeritas' flagship product, the V-Go, is the first, simple, wearable, basal-bolus insulin delivery solution for patients with Type 2 diabetes that enables patients to administer a physiological, continuous, preset basal (continuous) rate infusion of insulin over 24 hours. It also provides on demand bolus dosing at mealtimes. It is the only basal bolus insulin delivery system on the market today specifically designed keeping in mind the needs of type 2 diabetes patients. Headquartered in Bridgewater, New Jersey, Valeritas operates its R&D; functions in a state-of-the-art facility in Shrewsbury, Massachusetts. For more information, please visit www.valeritas.com.
Press Contact:
Marjie Hadad
MH Communications
[email protected]
908-947-0378